GlassScriptPhysician profile
Sheila Cherian
NPI 1992891956
$4,790.99
in general payments reported to CMS, 2019-2025
22 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $313 · 2021: $351 · 2022: $523 · 2023: $917 · 2024: $1,243 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.20 |
| Education | $204.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $893.08 | 2019-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $836.03 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $520.27 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $430.32 | 2020-2025 | Acthar |
| Novo Nordisk INC | $281.18 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $235.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $231.48 | 2023-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $202.01 | 2019-2022 | |
| Vifor Pharma, INC. | $197.59 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $169.02 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.90 | 2023-2025 | Jardiance |
| Amgen INC. | $114.67 | 2019-2025 | Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $111.71 | 2023-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $73.06 | 2019-2024 | Velphoro |
| Alnylam Pharmaceuticals INC. | $53.66 | 2024 | Oxlumo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $51.38 | 2022-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $44.97 | 2022-2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $44.89 | 2023-2024 | Rayaldee |
| Travere Therapeutics, INC. | $40.75 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $38.70 | 2025 | Empaveli |
| Janssen Pharmaceuticals, INC | $35.14 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $28.63 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.